Content
71%Weight 40%Scale 1-5Reviews the quality of instructions and guidance provided to agents. Good implementation is clear, handles edge cases, and produces reliable results.
A well-structured, actionable workflow body with real commands, named tools, and explicit validation/feedback loops. The dominant defect is bundle-level: the referenced `templates/protocol_template.md` is missing, which undermines Step 5 assembly and leaves one Reference Files entry dangling.
Suggestions
Ship the missing `templates/protocol_template.md` in the bundle — it is referenced in Step 5 and the Reference Files table but does not exist — or remove the reference and inline the 9 section headings so assembly works without it.
Give Step 5 an explicit completion check (e.g. 'confirm all 9 sections from the guide are filled and every numeric claim traces to a tool call') to close the workflow's final validation gap.
Deduplicate the tool listings (Step 2 pathway table vs Step 3 core-tools list) and consolidate the three repeated explanations of the relationship to `tooluniverse-clinical-trial-design` into one section.
| Dimension | Reasoning | Score |
|---|---|---|
Conciseness | The body is lean and assumes domain competence — no explanation of what a clinical trial or ICH E6 is, and the anti-fabrication rule is stated once as a terse callout ('LOOK UP, DON'T GUESS'). Minor redundancy keeps it below 5: the drug/device tool names appear in both the Step 2 table and the Step 3 core-tools list, and the relationship to `tooluniverse-clinical-trial-design` is explained three times (intro paragraph, NOT-for section, Integration section). Not 3: there is no genuine padding or teaching of known concepts. | 4 / 5 |
Actionability | Mostly executable: copy-paste-ready commands for all three calculator modes plus `--self-test`, and exact ToolUniverse tool names per section (e.g. `get_clinical_trial_eligibility_criteria`, `FDA_OrangeBook_get_exclusivity`). One real gap: Step 5 directs 'Fill `templates/protocol_template.md`', but that file does not exist in the bundle, so the final assembly step has no executable target. Not 3: the bulk of the guidance is concrete and runnable, not pseudocode or high-level hints. | 4 / 5 |
Workflow Clarity | A clear 5-step sequence with explicit branch points (Step 1 if/else on feasibility inputs, Step 2 drug/device fork), explicit validation (`--self-test` verifies all three formulas), and a genuine feedback loop ('if you don't have a defensible effect-size assumption yet, go back to Step 3'). Not 5: the final step dead-ends at the missing template file and there is no completeness check on the assembled document. Not 3: checkpoints are explicit and recoverable, not implicit. | 4 / 5 |
Progressive Disclosure | Structure and signaling are good — a Reference Files table with per-file descriptions, one-level-deep references, and section-by-section detail correctly delegated to `references/protocol_sections_guide.md`. But scored against the actual bundle, one of the four referenced files, `templates/protocol_template.md`, does not exist, and it is the file the entire Step 5 assembly depends on. A dangling reference that breaks navigation at the deliverable-assembly step is more than the 'minor organization gaps' of the 4 anchor. | 3 / 5 |
Total | 15 / 20 Passed |